Compare VIR & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | PDX |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | NY |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.1M | 931.2M |
| IPO Year | 2019 | N/A |
| Metric | VIR | PDX |
|---|---|---|
| Price | $7.61 | $19.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.63 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | N/A |
| Earning Date | 02-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $13.52 |
| 52 Week High | $11.39 | $21.05 |
| Indicator | VIR | PDX |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 47.43 |
| Support Level | $5.80 | $19.22 |
| Resistance Level | $6.90 | $20.07 |
| Average True Range (ATR) | 0.47 | 0.37 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 92.50 | 77.70 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.